Efalizumab

Nature Reviews Drug Discovery

Volumn 3, Issue 6, 2004, Pages 473-474

  Marecki, Sylvia ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CELL SURFACE PROTEIN; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY; RETINOID DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; SKIN DISEASE;

EID: 3042593134     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1420     Document Type: Article

References (5)

1. Greaves, M. W. & Weinstein, G. D. Treatment of psoriasis. N. Engl. J. Med. 332, 581-588 (1995).
2. Christophers, E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26, 314-320 (2001).
3. Krueger, J. G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1-23 (2002).
4. Werther W. A. et al. Humanization of an anti-lymphocyte function associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157, 4986-4995 (1996).
5. FDA labelling information [online] (cited 22 March 2004) http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf